Advances in Gene Therapies for Retinal Disorders: Individualized Management of Patients
Synchronous In-Person Symposium
Thank you for attending. Please click "Take Post-Test" below to proceed to the posttest, evaluation, and claim your credit.
Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous in-person symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
Details
Overview
Introduction and Overview: Where We’ve Come in Gene Therapy by Allen Ho, MD Ocular Gene Therapy Delivery by Robert Avery, MD Gene Therapy for Wet AMD: Current Clinical Trials by Jeffrey Heier, MD Changing Retinal Landscape and Implications for Future Therapies by Pravin Dugel, MD Case Discussion Closing Comments and CME posttest by Allen Ho, MD Supported by an educational grant from REGENXBIO Inc. Learning Objectives
- Describe gene therapy and how it may be used in treating retinal disorders.
- Distinguish between gene addition, gene augmentation, and gene editing.
- Explain which retinal disorders are likely to benefit from gene therapy.
- Differentiate the various gene therapy delivery methods and the differences among them.
Accreditation
Accreditation Statement Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians Credit Designation Statement Evolve Medical Education LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Faculty and Disclosures
DISCLOSURE POLICY
Allen C. Ho, MD, FACS Professor of Ophthalmology Thomas Jefferson University Director of Retina Research Wills Eye Hospital Philadelphia, PA Mid Atlantic Retina Chief Medical Editor, Retina TodayRobert Avery, MD California Retina Consultants Santa Barbara, CA Associate Medical Editor, Retina TodayPravin U. Dugel, MD Managing Partner, Retinal Consultants of Arizona Phoenix Clinical Associate Professor of Ophthalmology, Doheny Eye Institute, Keck School of Medicine, University of Southern California Physician Executive Director, Banner Eye Institute Phoenix, AZ Founding Partner, Spectra Eye Institute Sun City, AZ Retina Today Editorial Board Member Jeffrey S. Heier, MD Co-President and Medical Director Director of the Vitreoretinal Service Director of Retina Research Ophthalmic Consultants of Boston DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Robert Avery, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Amgen, Apellis, Bausch + Lomb, Clearside, Eyepoint, Genentech, Helio, lridex, Notal, Novartis, OcularTheraputix, Regeneron, Replenish, and Santen. Grant Research: Genentech. Shareholder: Alcon, Novartis, Regeneron, and Replenish. Pravin U. Dugel, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/ Advisory Board Member: Abbott/AMO, Acucela, Aerie Pharmaceuticals, Aerpio, Alcon, Alimera Sciences, Allergan, Amgen, Annidis, ArticDX, Avalanche, Bausch + Lomb, Boehringer lngelheim, ByeOnics, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Clearside Biomedical, CDR-Life, Inc., Digisight, Dose Medical, Genentech, Graybug Vision, lrenix, Kodiak Sciences, Lutronic, Lux Bioscience, Macusight, NeoVista, Neurotech, Novartis, Oculis, Ophthotech, Omeros, Opthea, Optovue, ORA, Orbis International, Panoptica, Pentavision, pSivida Corporation, QLT, Inc., Regeneron, Roche, Santen, SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenetics, Topcon, and TrueVision. Stock/Shareholder: Aerpio, Alimera, Annidis, ArctixDx, Clearside Biomedical, Digisight, lrenix, Ophthotech and PanOptica. Jeffrey S. Heier, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: 4DMT, Aerie, Aerpio, AKROS, Alkahest, Apellis, Array, Asclepix, Bayer, Biomarin, Beaver Visitec lnt'I, Daiichi, Eloxx, Galecto, Galimedix, Genentech, Generation Bio, Helie, Interface, lrenixx, Janssen, Kala, Kanghong, Kodiak, Notalvision, Novartis, Omeicos, Orbit Bioemedical, Regeneron, RegenXBio, Retrotope, Scifluor, Shire, Stealth BioTherapeutics, Thrombogenics, Voyant, and Zeiss. Grant Research: Aerpio, Apellis, Clearside, Daiichi, Foreseehome, Genentech, Genzyme, Hemera, Janssen, Kalvista, Kanghong, Novartis, Ocudyne, Ophthotech, Optos, Optovue, Regeneron, RegenXBio, and Thrombogenics. Shareholder: Adverum,Aldeyra, Allegro, Digital Surgery Systems, Ocular Therapeutics, and Jcyte. Allen C. Ho, MD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerpio, Aerie, Alcon, Allergan, Asclepix, Beaver EndoOptiks, BioTime, Chengdu Kang Hong, Eloxx, Everads, Genentech, Janssen, Notal, Ocugenix, ONL, Optovue, Orbit Biomedical, PanOptica, PRN, ProQR, Regeneron, RegenxBio, Sanofi, and Second Sight. Grant Support: Aerie, AGTC, Alcon, Allergan, Apellis, Chengdu Kang Hong, Genentech, Janssen, NEI/NIH, ProQR, Regeneron, RegenxBio, Sanofi, and Second Sight. Ownership: Covalent, ONL, PanOptica, PRN, and Visionary Ventures. Editorial Support Disclosures Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
Off-Label Statement This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or REGENEXBIO Inc. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
- NEW EPISODEMinuteCE®
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
1.00 program creditDouglas K. Devries, OD
Cecelia Koetting, OD, FAAO
